(Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

				U.:	S. PATENTS	
		Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments		
	1.	2928833		1960-03-15	Leake et al	
	2.	4005208		1977-01-25	Bender	
	3.	4599338		1986-07-08	Regnier et al.	This patent appears to be an English language equivalent to EP0149578 cited herein.
	4.	5041448		1991-08-20	Janssens	
	5.	5051517		1991-09-24	Findeisen	This patent appears to be an English language equivalent toEP0399285 cited herein.
	6.	5223499	I _A	1993-06-29	Greenlee	
	7.	5234897	A	1993-08-10	Findeisen et al.	
	8.	5258380	A	1993-11-02	Janssens	
	9.	5266555	A	1993-11-30	Findeisen et al.	This patent appears to be an English language equivalent toEP0524482 cited herein.
	10.	5389642	A	1995-02-14	Dorsch	
	11.	5470579	A	1995-11-28	Bonte et al.	This patent appears to be an English language equivalent toWO9107945 cited herein.
	12.	5719279	A	1998-02-17	Kuefner-Muhl et al.	This patent appears to be an English language equivalent toWO94/03456 cited herein.
	13.	5753635	A	1998-05-19	Buckman	
	14.	6303661	B1	2001-10-16	Demuth	
	15.	6342601	B1	2002-01-29	Bantick	
	16.	6548481	B1	2003-04-15	Demuth et al.	
	17.	6579868	B1	2003-06-17	Osamu Asano	
	18.	6821978	B2	2004-11-23	Chackalamannil	
	19.	6869947	B2	2005-03-22	Kanstrup	
	20.	7060722	B2	2006-06-13	Kitajima	
	21.	7074794	B2	2006-07-11	Kitajima	This patent appears to be an English language equivalent toWO2002/14271 cited herein.
	22.	7074798	B2	2006-07-11	Yoshikawa	
	23.	7074923	B2	2006-07-11	Dahanukar	
	24.	7109192	B2	2006-09-19	Hauel	
	25.	7179809	B2	2007-02-20	Eckhardt	
	26.	7183280	B2	2007-02-27	Himmelsbach	
	27.	7192952	B2	2007-03-20	Kanstrup	
	28.	7217711	B2	2007-05-15	Eckhardt	
	29.	7235538	B2	2007-06-26	Kanstrup et al.	

U.S. PATENT APPLICATION PUBLICATIONS

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation if not in conformance and not considered. Include of	itation is in conformance with MPEP Section 609; Draw line through copy of this form with next communication to applicant.

(Use several sheets if necessary)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

Examiner Initial*			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear of Relevant Comments		
	1.	11/744700		2007-05-04	Sieger	Relevant Comments
	2.	11/744701		2007-05-04	Kohlrausch	
	3.	2002/0161001	A1	2002-10-31	Kanstrup	
	4.	2002/0161001	A1	2002-10-31	Chackalamannil et al.	
	7.	2002/0169174	- AI	2002-11-14	Chackalamannii et al.	This document appears to be an apparent
	5.	00000000000		0000 40 00		English language equivalent to
		2002/0198205	A1	2002-12-26	Himmelsbach	WO2002068420 cited herein.
	6.	2003/0199528	A1	2003-10-23	Kanstrup	
	7.	2003/0232987	A1	2003-12-18	Dahanukar et al.	
	8.	2003/0236272	A1	2003-12-25	Carr	
	9.	2003/0105077	A1	2003-06-05	Kanstrup, A.B. et al.	
	10.	2004/0034014	A1	2004-02-19	Kanstrup, A.B. et al.	
	11.	2004/0077645	A1	2004-04-22	Himmelsbach et al.	This document appears to be an apparent English language equivalent to WO2002068420 cited herein.
	12.	2004/0087587	A1	2004-05-06	Himmelsbach	
	13.	2004/0116328	A1	2004-06-17	Yoshikawa et al.	This document appears to be an apparent English language equivalent to WO03104229 cited herein.
	14.	2004/0138215	A1	2004-07-15	Eckhardt	This document appears to be an apparent English language equivalent to WO2004/046148 cited herein.
	15.	2005/0020574	A1	2005-01-27	Hauel, N. et al.	
	16.	2005/0026921	A1	2005-02-03	Eckhardt	
	17.	2005/0130985	A1	2005-06-16	Himmelsbach	
	18.	2005/0171093	A1	2005-08-04	Eckhardt et al.	
	19.	2005/0187227	A1	2005-08-25	Himmelsbach et al.	
	20.	2005/0203095	A1	2005-09-15	Eckhardt	
	21.	2005/0234108	A1	2005-10-20	Himmelsbach et al.	
	22.	2005/0261352	A1	2005-11-24	Eckhardt	
	23.	2006/0004074	A1	2006-01-05	Eckhardt	
	24.	2006/0058323	A1	2006-03-16	Eckhardt et al.	
	25.	2006/0063787	A1	2006-03-23	Yoshikawa	
	26.	2006/0094722	A1	2006-05-04	Yasuda	This document appears to be an apparent English language equivalent to WO2004/028524 cited herein.
	27.	2006/0142310	A1	2006-06-20	Pfrengle et al.	This document appears to be an apparent English language equivalent to WO2006/048427 cited herein.
	28.	2006/0173056	A1	2006-08-03		TTO ECOCIOTO TO TEL CITE CITE CITE CITE CITE CITE CITE CITE
	29.	2006/0205711	A1		Himmelsbach	This document appears to be an apparent English language equivalent to DE10117803 cited herein.
	30.	2006/0247226	A1	2006-11-02	Himmelsbach	
	31.	2007/0027168	A1	2007-02-01	Pfrengle et al.	
	32.	2007/0088038	A1	2007-04-19		

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not	itation is in conformance with MPEP Section 609; Draw line through

(Use several sheets if necessary)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initial*	Cite No.	Publication Number			of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments		
	33.	2007/0093659	A1	2007-04-26	Bonfanti			
	34.	2007/0142383	A1	2007-06-21	Eckhardt			
	35.	2007/0281940	A1	2007-12-06	Dugi			
	36.	2007/0219178	A1	2007-09-20	Muramoto			

	FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments	√1
	1.	2136288	CA	A1	1995-05-24	Merck Patent GmbH	This document appears to be an apparent English language equivalent to EP0657454 cited herein	
	2.	2418656	CA	A1	2002-02-21	Mitsubishi Pharma Corporation		
	3.	2496249	CA	A1	2004-04-03	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004018468 cited herein	
	4.	2496325	CA	A1	2004-03-04	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO20040184687 cited herein	
	5.	2505389	CA	A1	2004-05-21	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004041820 cited herein	
	6.	2508233	CA	A1	2004-06-17	Bl Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004050658 cited herein	
	7.	2529729	CA	A1	2004-12-23	BI International GmbH	This document appears to be an apparent English language equivalent to WO2004111051 cited herein	
	8.	2543074	CA	A1	2005-06-30	Bl International GmbH	This document appears to be an apparent English language equivalent to WO2005/058901 cited herein	
	9.	2555050	CA	A1	2005-09-15	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/085246 cited herein	
	10.	2556064	CA	A1	2005-09-09	Bl International GmbH	This document appears to be an apparent English language equivalent to WO2005/082906 cited herein	
	11.	2590912	CA	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	This document appears to be an English language equivalent to WO2006068163 cited herein	
	_12.	10109021	DE	A1	2002-09-05	Boehringer Ingelheim Pharma KG	US2006/0205711 cited herein appears to be an apparent English language equivalent	

 $^{^{1}}$ $\sqrt{\text{indicates English Language translation is attached}}$

Examiner:	Date Considered:	L
*Examiner: Initial if citation considered, whether or not c	itation is in conformance with MPEP Section 609; Draw line through	
citation if not in conformance and not considered. Include	copy of this form with next communication to applicant	L

INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

Boehringer Ingelheim	
13. 10117803 DE A1 2002-10-24 Pharma KG	
US4599338 cited he an apparent English 14. 0149578 EP A2 1985-07-24 ADIR equivalent	
14. 0149576 EP AZ 1965-07-24 ADIR (equivalent	erein annears to he
15. 0399285 EP A1 1990-11-28 Bayer AG equivalent	
16. 0400974 EP A2 1990-05-12 Merck & Co. Inc.	
17. 0412358 EP A1 1991-02-13 Bayer AG	√
US5266555 cited he an apparent English 18. 0524482 EP A1 1993-01-27 Bayer AG equivalent	language
CA2136288 cited he an apparent English 19. 0657454 EP A1 1995-06-14 Merck Patent GmbH equivalent	
20. 1054012 EP A1 2000-11-22 Eisai Co. Ltd	
21. 1338595 EP A2 2003-08-27 Eisai Co. Ltd	
22. 1514552 EP A1 2005-03-16 Eisai Co. Ltd	
Takeda Pharmaceutical	
and the state of t	
24. 385302 ES A1 1973-04-16 Laboratorios Miquel	ν
25. 2707641 FR A1 1995-01-20 Fournier Ind. Et Sante	
26. 2003/300977 JP 2003-10-21 Co. Ltd	√,
27. 2006/045156 JP 2006-02-16 Sumitomo Pharma	V
28. \$37-4895 JP Yoshitomi 1962-06-16 Pharmaceutical Corp.	√
29. 91/07945 WO A1 1991-06-13 LVMH Recherche equivalent	language
US\$719279 cited he Boehringer Ingelheim an apparent English an apparent English equivalent St.	
31. 99/29695 WO A1 6/17/1999 Astra Aktiebolag	
US7074794 cited he an apparent English 32. 2002/14271 WO A1 2002-02-21 Welfide Corporation equivalent	
33. 2003/024965 WO A2 2003-03-27 Novo Nordisk A/S	
34. 2003/057200 WO A2 2003-07-17 Novo Nordisk A/S	
34. 2003/05/200 WO A2 2003-07-17 Novo Nordisk A/S Boehringer Ingelheim CA2496325 cited he	erein appears to be
Pharma GmbH & Co. an apparent English 35. 2004/018467 WO A2 2004-03-04 KG equivalent	language
Bochringer Ingelheim CA2496249 Cited In- Pharma GmbH & Co. an apparent English 2004-03-04 KG an apparent English equivalent	language
US2006/0094722 ci to be an apparent E 37. 2004/028524 WO A1 2004-04-09 Eisai Co., Ltd. equivalent	
38. 2004/033455 WO A2 2004-04-22 Novo Nordisk	

Examiner:	Date Considered:					
*Examiner: Initial if citation considered whether or not ci	tation is in conformance with MPEP Section 609. Draw line through					

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

			FOREIG	N PATENT I	OCUMENTS		
39.	2004/041820	wo	A1	2004-05-21	Boehringer Ingelheim Pharma GmbH	CA2505389 cited herein appears to be an apparent English language equivalent	
40.	2004/046148	wo	A1	2004-06-03		US2004/0138215 cited herein appears to be an apparent English language equivalent	
41.	2004/048379	wo	A1	2004-06-10	Sumitomo Pharm Co., Ltd.		V
42.	2004/050658	wo	A1	2005-06-17		CA2508233 cited herein appears to be an apparent English language equivalent	
43.	2004/096806	wo	A1	2004-11-11			V
44.	2004/108730	wo	A1	2004-12-16	Fujisawa Pharma. Co., Ltd.		
45.	2004/111051	wo	A1	2005-12-23	Bi Int'i GmbH	CA2529729 cited herein appears to be an apparent English language equivalent	
46.	2005/058901	wo	A1	2005-06-30	Bi Int'i GmbH	CA2543074 cited herein appears to be an apparent English language equivalent	
47.	2005/082906	wo	A1	2005-09-09	Bi Int'i GmbH	CA2556064 cited herein appears to be an apparent English language equivalent	
48.	2005/085246	wo	A1	2005-09-15	Bi Int'i GmbH	CA2555050 cited herein appears to be an apparent English language equivalent	
49.	2006/029769	wo	A1	2006-03-23	BI Pharma GmbH & Co. KG	US2006079541 cited herein appears to be an apparent English language equivalent	
50.	2006/048427	wo	A1	2006-05-11	Bi Int'i GmbH	US2006142310 cited herein appears to be an apparent English language equivalent	
51.	2006/068163	wo	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	CA2590912 cited herein appears to be an English language equivalent	
52.	2007/017423	wo	A2	2007-02-15	F. Hoffmann-La Roche AG		

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initial*	Cite No.						
	1.	AUGUSTYNS, K. et al., The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD 26) and the Therapeutic Potential of DPP-IV Inhibitors, Current Medicinal Chemistry, Vol. 6, No. 4, 1999, pp. 311-327.					
	2.	BELJEAN-LEYMARIE et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazo[4,5-d]pyridazinones-4, Can. J. Chem., Vol. 61, No. 11, 1983, pp. 2563-2566.	√				
	3.	BOLLAG, R.J. ET AL; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," Endocrinology, Vol. 141, No. 3, 2000, pp. 1228-1235.					
	4.	BRITTAIN, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," Polymorphism in Pharmaceutical Solids, 1999, p. 235-238					

 $^{^2~\}sqrt{}$ indicates English Language translation is attached

	Examiner:	Date Considered:				
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through						
	citation if not in conformance and not considered. Include of	copy of this form with next communication to applicant.	ı			

(Use several sheets if necessary)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

5.	BUSSO ET AL., "Circulating CD26 is Negatively Associated with Inflammation in Human and Experimental Arthritis," Am. J. Path., Vol. 166, No. 2, Feb. 2005, pp. 433-442.	
	CAIRA, M.R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, Springer, Berlin, Vol. 198, 1998, p. 163-208	Τ
7.	CONAFELLO, S.I. ET Al.; "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance," PNAS 2003; 100:6825-6830; originally published online May 14, 2003; information current as of December 2006. www.pnas.org/cg/content/full/100/116825.	_
8.	DEACON, C.F. ET AL; "Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2 diabetes: a historical perspective;" Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4.	
9.	DeMEESTER, I. ET AL.; "CD26, let it cut or cut it down", Review: Immunology Today; August 1999, Vol. 20, No. 8 pp.367-375	Т
10.	KOROM, S. ET AL; "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients ¹² , Transplantation, May 27, 1997, Vol. 63, no 10, pp 1495-1500.	
	POSPISILIK, ET AL; "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β -Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats; Diabetes, Vol. 52, March 2003 pp 741-750.	
	RHEE ET AL.: "Nitrogen-15-Labeled Deoxynucleosides. 3. Synthesis of [3-15N]-2'-Deoxyadenosine" J. Am. Chem. Soc. 1990, 112, 8174-8175	
	SEDO, A. ET AL; "Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?" Arthritis Research & Therapy 2005, Vol. 7, pp. 253-269	Τ
	TANAKA, S., ET AL; "Suppression of Arthritis by the Inhibitors of Dipeptidyl Peptidase IV," In. J. Immunopharmac., Vol. 19, No. 1, pp. 15-24, 1997	_
	WOLFF, M.E.: "Surger's Medicinal Chemistry and Drug Discovery" Fifth Edition, Vol 1: Principles and Practice, pgs. 975- 977, 1994, John Wiley & Sons, Inc.,	_
	ZHONG, QING ET AL; "Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-β release from MG- 63 cells," Peptides 24 (2003) 611-616	Τ
	Chemical Abstracts Accession No. 1987:95577: Abstract of ROMANENKO et al., "Synthesis and biological activity of 3- methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Farmatsevtichnii Zhurnai, 1986, (Kiev), Vol. 5, 1986, pp. 41-44.	
	Chemical Abstracts Accession No. 106:95577 ROMANENKO ET AL., "Synthesis and biological activity of 3-methyl, 7-or 8-alkyl-7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Zaporozh. Med. Institute (1986)	_
	YOSHIKAWA, SEIJI ET AL.: Chemical Abstract of Japanese Patent No. WO 2003/104229 *Preparation of purinone derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors	
20.	International Search Report for PCT/EP03/09127 mailed November 28, 2003.	
21.	International Search Report for PCT/EP03/13648 mailed April 5, 2004.	
22.	International Search Report for PCT/EP2007/054270 mailed August 14, 2007.	
23.	International Search Report for PCT/EP2007/058181 mailed November 28, 2007.	
24.	International Search Report for PCT/EP2007/054204 mailed August 3, 2007.	
25.	International Search Report for PCT/EP2007/054201 mailed August 29, 2007	

Examiner:					Date Conside					
ı	400	X 1-1 4 10 11				0	1.1.3.40000.0	 	 	-